drugset / Trial / NCT05919407
Pyridostigmine and Amifampridine for Myasthenia Gravis
RandomizedCrossoverQuadruple-blindTreatment
Summary
A randomized, double-blind, placebo controlled, crossover intervention study evaluating the effect of pyridostigmine (part 1) and amifampridine (part 2) in Myasthenia Gravis (MG).
Timeline
- Start
- 2023-03-22
- Primary completion
- 2024-09-22
- Completion
- 2024-09-22
Publications
- Remijn-Nelissen L, Bakker WR, van den Hout WB, van Gelder T, Ruiter AM, Campman YJM, Badrising UA, Straathof CSM, Verschuuren JJGM, Tannemaat MR. Efficacy of Pyridostigmine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial. Neurology. 2026 Apr 28;106(8):e214865. doi: 10.1212/WNL.0000000000214865. Epub 2026 Apr 7.
- Remijn-Nelissen L, Bakker WR, van Gelder T, Moes DJAR, Ruiter AM, Campman YJM, Badrising UA, Straathof CSM, Verschuuren JJGM, Tannemaat MR. Efficacy and Safety of Amifampridine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial. Neurology. 2026 Apr 28;106(8):e214715. doi: 10.1212/WNL.0000000000214715. Epub 2026 Apr 7.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amifampridine | Small molecule | 15 mg | — |
| Subject | Amifampridine | Small molecule | 30 mg | — |
| Subject | Pyridostigmine | Small molecule | 10 mg | — |